ERBB2 and neoplasm: Notably, many CAR-Ts targeting tumor-associated antigens may have potential on-target/off-tumor toxicities, such as HER2, GD2, Claudin18.2, etc. More optimized CAR structural designs need to be developed to enable CAR-T to be widely used in the treatment of solid tumors.